TL;DR: Aetna, a CVS Health company, modified CPB 0534 governing vesicoureteral reflux treatment by endoscopic injection of bulking agents, effective November 27, 2025. Here's what billing teams need to do.
This update to the Aetna vesicoureteral reflux coverage policy clarifies both the medical necessity criteria for covered procedures and the list of agents Aetna deems experimental. The primary procedure code affected is CPT 52327 (cystourethroscopy with subureteric injection of implant material). HCPCS codes L8604 and L8606 cover the two most commonly billed injectable agents — dextranomer/hyaluronic acid copolymer (Deflux) and synthetic implant material — and your billing team needs to know exactly which agents are covered and which ones will trigger a claim denial before the next VUR case hits the queue.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Vesicoureteral Reflux Treatment by Endoscopic Injection of Bulking Agents |
| Policy Code | CPB 0534 |
| Change Type | Modified |
| Effective Date | November 27, 2025 |
| Impact Level | Medium |
| Specialties Affected | Pediatric Urology, Urology, Nephrology, Pediatric Surgery |
| Key Action | Audit your injectable agent documentation against the approved list — any claim using an experimental agent (e.g., Bulkamid, Vantris, Contigen) will not be reimbursed |
Aetna Vesicoureteral Reflux Coverage Criteria and Medical Necessity Requirements 2025
The Aetna VUR coverage policy under CPB 0534 Aetna system covers endoscopic injection of bulking agents for vesicoureteral reflux — but only for specific agents and only when defined criteria are met.
The approved agents are: dextranomer/hyaluronic acid copolymer (Deflux), polydimethylsiloxane (Macroplastique), polytetrafluoroethylene (Teflon), or any other bulking agent with current FDA approval for VUR treatment. If the agent your provider used isn't on that list, don't expect reimbursement.
Medical Necessity Criteria
For coverage of CPT 52327, the member must have primary or secondary VUR, and conservative treatments must have already failed. Aetna defines conservative treatments as prophylactic antibiotics and clean intermittent catheterization.
After that baseline, the member must meet at least one of these eight conditions:
| # | Covered Indication |
|---|---|
| 1 | A child with a previously unsuccessful ureteral re-implantation |
| 2 | A child who stopped medication due to drug intolerance or parental non-compliance |
| 3 | A child whose reflux is associated with a thick-walled neuropathic bladder |
| 4 | Deterioration of renal parameters, regardless of reflux severity |
| 5 | Lower grades of reflux (grades I through III) |
| 6 | Persistent reflux in a post-pubertal female member |
| 7 | Recurrent, poorly controlled febrile urinary tract infections |
| 8 | Symptomatic VUR after renal transplantation |
The real issue here is criteria five. Grades I–III VUR covers a broad swath of patients. Combined with the febrile UTI criterion, Aetna's coverage policy is reasonably generous on the clinical side. The documentation burden is on your team to prove conservative treatment failure before the endoscopic injection claim goes out.
The Three-Session Ceiling
Aetna draws a hard line at three treatment sessions. If a member doesn't respond after three rounds, Aetna classifies them as a treatment failure. Further sessions are not considered medically necessary. This is not a soft limit — sessions beyond three will not be covered, and any prior authorization you have for this procedure should be understood in that context.
If your practice sees patients who've had two sessions elsewhere with no improvement, flag that patient record immediately. A third session billed without proper documentation of the prior failure pattern is a denial waiting to happen.
Prior Authorization Considerations
CPB 0534 doesn't explicitly state prior authorization requirements within the medical necessity criteria, but Aetna commonly requires prior auth for surgical procedures of this type. Before billing CPT 52327, confirm prior authorization status through the member's specific plan. Don't assume the policy-level coverage criteria substitute for plan-level prior auth requirements.
Aetna Vesicoureteral Reflux Exclusions and Non-Covered Indications
This is where your billing team needs to pay close attention. Aetna classifies nine specific injectable agents as experimental, investigational, or unproven for VUR treatment. Claims using these agents will be denied.
The excluded agents are:
| # | Excluded Procedure |
|---|---|
| 1 | Autologous blood |
| 2 | Calcium hydroxyapatite |
| 3 | Chondrocytes |
| 4 | Durasphere |
| 5 | Fat |
| 6 | Glutaraldehyde cross-linked bovine dermal collagen (Contigen, Zyplast) |
| 7 | Myoblasts |
| 8 | Polyacrylamide hydrogel (Bulkamid) |
| 9 | Polyacrylate-polyalcohol copolymer (Vantris) |
Some of these — Bulkamid and Vantris in particular — are actively marketed for urological bulking procedures in other contexts. Your clinical staff may be familiar with them from stress urinary incontinence cases. They are not covered for VUR under this policy.
The HCPCS codes for chondrocytes, fat, and myoblasts are grouped together in the policy with the note that no specific HCPCS code exists for these agents. Calcium hydroxyapatite maps to Q2026 (Injection, Radiesse, 0.1 ml), and glutaraldehyde cross-linked bovine collagen maps to L8603. Both are listed in the non-covered group.
If your provider bills L8603 or Q2026 for a VUR case, expect a denial. These HCPCS codes appear under the non-covered group in CPB 0534, regardless of the clinical rationale documented.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Failed ureteral re-implantation (pediatric) | Covered | CPT 52327, L8604, L8606 | Conservative treatment failure required |
| Drug intolerance or parental non-compliance with medication | Covered | CPT 52327, L8604, L8606 | Document specific reason for medication failure |
| Thick-walled neuropathic bladder (pediatric) | Covered | CPT 52327, L8604, L8606 | Conservative treatment failure required |
| Deterioration of renal parameters | Covered | CPT 52327, L8604, L8606 | Applies regardless of reflux grade or severity |
| Grades I–III VUR (lower grades) | Covered | CPT 52327, L8604, L8606 | Conservative treatment failure required |
| Persistent reflux in post-pubertal females | Covered | CPT 52327, L8604, L8606 | Conservative treatment failure required |
| Recurrent febrile urinary tract infections | Covered | CPT 52327, L8604, L8606 | Must be poorly controlled; document frequency |
| Symptomatic VUR after renal transplantation | Covered | CPT 52327, L8604, L8606 | Secondary VUR covered under this indication |
| Members not meeting any listed criterion | Not Covered | CPT 52327 | Aetna considers experimental/investigational |
| 4th+ treatment session (non-responders) | Not Covered | CPT 52327 | Aetna classifies as treatment failure after 3 sessions |
| Injection with Bulkamid (polyacrylamide hydrogel) | Experimental | L8606 grouping — no specific code | Not covered regardless of clinical rationale |
| Injection with Vantris (polyacrylate-polyalcohol copolymer) | Experimental | No specific code | Not covered regardless of clinical rationale |
| Injection with autologous fat, blood, myoblasts, or chondrocytes | Experimental | No specific code | No applicable HCPCS — claim will lack valid code and coverage |
| Injection with Durasphere | Experimental | No specific code | Not covered |
| Injection with calcium hydroxyapatite (Radiesse) | Experimental | Q2026 | Specifically excluded under this policy |
| Injection with glutaraldehyde cross-linked collagen (Contigen/Zyplast) | Experimental | L8603 | Specifically excluded under this policy |
Aetna Vesicoureteral Reflux Billing Guidelines and Action Items 2025
The November 27, 2025, effective date is already in effect. If your team hasn't reviewed your VUR charge capture against these criteria, do it now.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 52327 and L8604/L8606 immediately. Confirm every claim includes documentation of: the specific VUR grade, the conservative treatments attempted, the reason those treatments failed, and which of the eight medical necessity criteria the member meets. A claim without this documentation chain is a denial in progress. |
| 2 | Cross-check which injectable agent your providers use. If your physicians use Bulkamid, Vantris, Contigen, Zyplast, Durasphere, or Radiesse for any VUR case, those claims are not covered under this policy. Talk to your medical director about whether your provider's agent selection matches Aetna's covered list before claims go out. |
| 3 | Track treatment session counts per member. Build a flag in your billing system for any Aetna member who has received two sessions of CPT 52327. A third session needs strong documentation. A fourth session will be denied. Your revenue cycle team should catch this before the claim drops, not after the denial comes back. |
| 4 | Confirm prior authorization before the procedure, not after. CPB 0534 sets the coverage policy framework, but individual Aetna plan designs may have additional prior authorization requirements for CPT 52327. Run prior auth verification for every VUR injection case — especially transplant recipients and pediatric neuropathic bladder patients, where documentation requirements are likely to be scrutinized closely. |
| 5 | Update your ICD-10 documentation to use the correct code range. Diagnosis codes N13.70 through N13.9 cover vesicoureteral-reflux. Make sure your encounter documentation specifies the correct reflux grade and whether it's primary or secondary. This matters for meeting the grade I–III coverage criterion — the medical record needs to support the specific criterion your team is citing. |
| 6 | Don't use L8603 or Q2026 for VUR cases. Both codes appear in the non-covered group under CPB 0534. HCPCS L8603 (injectable collagen implant) and Q2026 (Radiesse injection) are excluded agents for this indication. Billing these codes for a VUR diagnosis will trigger a claim denial. |
| 7 | If your case mix includes VUR billing for Aetna members, review the full CPB 0534 text. If you're not sure how a specific clinical scenario maps to the eight medical necessity criteria — especially for transplant patients or post-pubertal female members with complex histories — loop in your compliance officer before the claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vesicoureteral Reflux Treatment Under CPB 0534
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 52327 | CPT | Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material |
HCPCS Codes — Covered Agents
| Code | Type | Description |
|---|---|---|
| L8604 | HCPCS | Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies |
| L8606 | HCPCS | Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies |
HCPCS Codes — Non-Covered / Experimental Agents
| Code | Type | Description | Reason |
|---|---|---|---|
| L8603 | HCPCS | Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies | Glutaraldehyde cross-linked bovine collagen (Contigen, Zyplast) — experimental for VUR |
| Q2026 | HCPCS | Injection, Radiesse, 0.1 ml | Calcium hydroxyapatite — experimental for VUR |
| Q3031 | HCPCS | Collagen skin test | Associated with collagen agents — experimental for VUR |
Note: Chondrocytes, fat, myoblasts, autologous blood, Bulkamid, Durasphere, and Vantris have no specific HCPCS codes listed in CPB 0534. If billed, they would fall under unlisted procedure codes and are not covered for VUR under this policy.
Key ICD-10-CM Diagnosis Codes
| Code Range | Description |
|---|---|
| N13.70 – N13.9 | Vesicoureteral-reflux (includes unspecified, with and without reflux nephropathy, with hydroureter, bilateral and unilateral) |
Get the Full Picture for CPT 52327
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.